AR058438A1 - Utilizacion de la gonadotrofina corionica humana por via oral para el tratamiento del sobrepeso (obesidad) asociado a hipertension arterial, diabetes no insulino dependiente, hipercolesterolemia, dislipemias y lipodistrofias - Google Patents

Utilizacion de la gonadotrofina corionica humana por via oral para el tratamiento del sobrepeso (obesidad) asociado a hipertension arterial, diabetes no insulino dependiente, hipercolesterolemia, dislipemias y lipodistrofias

Info

Publication number
AR058438A1
AR058438A1 ARP060103147A ARP060103147A AR058438A1 AR 058438 A1 AR058438 A1 AR 058438A1 AR P060103147 A ARP060103147 A AR P060103147A AR P060103147 A ARP060103147 A AR P060103147A AR 058438 A1 AR058438 A1 AR 058438A1
Authority
AR
Argentina
Prior art keywords
lipodystrophies
treatment
hypercolesterolemia
gonadotrophine
dyslipemia
Prior art date
Application number
ARP060103147A
Other languages
English (en)
Inventor
Daniel Oscar Belluscio
Original Assignee
Daniel Oscar Belluscio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daniel Oscar Belluscio filed Critical Daniel Oscar Belluscio
Priority to ARP060103147A priority Critical patent/AR058438A1/es
Priority to US11/826,214 priority patent/US20080020972A1/en
Publication of AR058438A1 publication Critical patent/AR058438A1/es
Priority to US13/078,474 priority patent/US20110178012A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de la Gonadotrofina Carionica Humana por vía oral, en forma sublingual, para el tratamiento de pacientes obesos asociados con problemas de hipertension arterial, diabetes no insulino dependiente, hipercolesterolemia, dislipemias y lipodistrofias
ARP060103147A 2006-07-21 2006-07-21 Utilizacion de la gonadotrofina corionica humana por via oral para el tratamiento del sobrepeso (obesidad) asociado a hipertension arterial, diabetes no insulino dependiente, hipercolesterolemia, dislipemias y lipodistrofias AR058438A1 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ARP060103147A AR058438A1 (es) 2006-07-21 2006-07-21 Utilizacion de la gonadotrofina corionica humana por via oral para el tratamiento del sobrepeso (obesidad) asociado a hipertension arterial, diabetes no insulino dependiente, hipercolesterolemia, dislipemias y lipodistrofias
US11/826,214 US20080020972A1 (en) 2006-07-21 2007-07-13 Use of human chorionic gonadotropin orally for the treatment of overweight (obesity) associated with high blood tension, non-insulin-dependent diabetes, hypercholesterolemia, dyslipidemias and lipodystrophy
US13/078,474 US20110178012A1 (en) 2006-07-21 2011-04-01 Use of human chorionic gonadotropin orally for the treatment of overweight (obesity) associated with high blood tension, non-insulin-dependant diabetes, hypercholesterolemia, dyslipidemias and lipodystrophy.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP060103147A AR058438A1 (es) 2006-07-21 2006-07-21 Utilizacion de la gonadotrofina corionica humana por via oral para el tratamiento del sobrepeso (obesidad) asociado a hipertension arterial, diabetes no insulino dependiente, hipercolesterolemia, dislipemias y lipodistrofias

Publications (1)

Publication Number Publication Date
AR058438A1 true AR058438A1 (es) 2008-02-06

Family

ID=38972160

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103147A AR058438A1 (es) 2006-07-21 2006-07-21 Utilizacion de la gonadotrofina corionica humana por via oral para el tratamiento del sobrepeso (obesidad) asociado a hipertension arterial, diabetes no insulino dependiente, hipercolesterolemia, dislipemias y lipodistrofias

Country Status (2)

Country Link
US (2) US20080020972A1 (es)
AR (1) AR058438A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3120786B1 (fr) 2021-03-19 2023-02-10 Univ Claude Bernard Lyon système de stimulations TACTILES

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR061280A1 (es) * 2007-12-07 2008-08-20 Daniel Oscar Belluscio Utilizacion de la gonadotrofina corionica humana por via oral o inyectable en el tratamiento del sindrome metabolico

Also Published As

Publication number Publication date
US20110178012A1 (en) 2011-07-21
US20080020972A1 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
EA200900796A1 (ru) Пиперидиновые агонисты gpcr
EA200900880A1 (ru) Пиперидиновые агонисты gpcr
EA200900879A1 (ru) Пиперидиновые агонисты gpcr
CL2011000051A1 (es) Compuestos derivados de piperidinilo, agonistas del receptor acoplado a la proteina g; composicion farmaceutica que los comprende; y su uso para la regulacion de la saciedad, tratar la obesidad, diabetes, sindrome metabolico, intolerancia ala glucosa, hiperlipidemias o hipertension, entre otras enfermedades.
CL2008001049A1 (es) Compuestos derivados de benzamidas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, intolerancia a la glucosa, dislipidemia, hipertension, obesidad.
NO20080052L (no) G-Protein kopplede reseptoragonister
CL2012003053A1 (es) Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad.
NO20080010L (no) GPCR-agonister
CY1115004T1 (el) Φαρμακευτικοι συνδυασμοι ενος ανταγωνιστη υποδοχεων αγγειοτασινης και ενος αναστολεα νερ
CL2007003697A1 (es) Compuestos derivados de sulfonamida; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la hiperglucemia, diabetes, obesidad, hipertension, hiperlipidemia, sindrome metabol
CY1112483T1 (el) Αγωνιστες gpcr πιπεριδινης
DOP2012000006A (es) Agonista de gpr119
ATE516300T1 (de) Neuromedin-u-rezeptoragonisten und ihre verwendung
CY1110753T1 (el) Αναστολεις της 11-βητα-υδροξυστεροειδους αφυδρογονασης i
EA201170303A1 (ru) Аналоги глюкозозависимого инсулинотропного полипептида
SV2006002218A (es) Fenilaminotiazoles sustituidos y su uso ref.bhc041280-sv
PE20110841A1 (es) FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(ß-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO
CL2007002890A1 (es) Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad.
GT200600046A (es) Terapia de combinacion
ECSP099044A (es) Compuestos de pirimido fusionados
HK1158192A1 (en) Piperidine gpcr agonists
AR060880A1 (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
ATE342057T1 (de) Melanocortinrezeptoragonisten
DK1827427T3 (da) Aryloxyethylaminderivater med en kombination af partiel dopamin-D2 receptoragonisme og inhibition af genoptag af serotonin
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.

Legal Events

Date Code Title Description
FB Suspension of granting procedure